Moderate-to-Severe Atopic Dermatitis (Eczema)
Moderate-to-Severe Atopic Dermatitis (Eczema).
Tralokinumab monotherapy for moderate-to-severe atopic dermatitis ECZTRA 2 (ECZema Tralokinumab trial no.2)
The purpose of this trial is to test if the trial drug, tralokinumab, is better than placebo or ‘dummy treatment' at treating moderate to severe atopic dermatitis. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis, itch and several other symptoms, as well as general health status and quality of life.
In this trial, tralokinumab will be compared with placebo, which is an injection which contains no active material. Together, the tralokinumab and the placebo will be referred to as trial medication or trial treatment
The trial will last up to 72 weeks, and there will be up to 30 visits. The trial visits will typically be every 2weeks. Your study doctor will tell you when to come in for your trial visits. Not all assessments and procedures will be done at all visits, so how long a visit lasts, varies during the trial. Visits will take approximately 30 minutes to 2 hours depending on what needs to be done at that visit. There are 6 visits which will require you to be observed for 2 hours after receiving study medication.
You will not receive any payment for participating in this trial. If included in the trial you will be reimbursed for expenses up to $50.00 per trial visit to cover your travel expenses.
Unable to participate in this trial? Register for similar trials.